Ampio Pharmaceuticals, Inc.

Good afternoon and welcome to NPO Pharmaceuticals 2021 third quarter earnings result and corporate update call. I will be the event specialist running today's event. If you would like to ask a question today, please submit your questions on the webcast platform via the ask a question widget on the top right hand corner of your screen. As a reminder, this call is being recorded and all listeners will be on a listen only mode. At this time, I would like to turn the call over to Mr Dan Stokely, and PO's chief financial officer. Dan, please go ahead when you're ready.

Hi, everyone. Thank you very much, and I hope everyone's having a great day. It's our pleasure for me and certain members of the executive management team to be present today, and we'd like to thank each one of you for attending our third quarter 2021 earnings and business update call. Prior to reading the Safe Harbor forward-looking statement, I would like to introduce you to the members of the executive team who will be presenting and or participating on the call today. First is Holly Cherevka, the company's president and chief operating officer. We also have President Howard Levy, the company's chief medical officer, Dr. David Baror, director and founder, and myself, Dan Stokely, the chief financial officer. I'd like to start out by first reading our safe harbor statement. The presentation and any follow-up responses to Q&A may contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements, as these statements are based upon our current expectations, forecasts, and assumptions, and are subject to significant risks and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements, include but are not limited to the matters listed under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2020, which is on file with the Securities and Exchange Commission, as well as other risk details and subsequent filings with the Securities and Exchange Commission. These reports are available at www.sec.gov. Statements and information in this presentation include forward-looking statements, speak only as of the date they are made or provided unless earlier data is indicated, and we do not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise except as required by law. Now I'd like to provide a financial update. I would like to discuss our financial results for the three- and nine-month period ending September 30, 2021. Cash and cash equivalents totaled $17.1 million as of September 30, 2021, compared to $17.3 million on December 31, 2020. The net decrease of $0.2 million is attributable to cash required to fund the operating activities of the company, totaling $10.4 million, which was partially offset by net proceeds received from the utilization of our at-the-market equity offering program and stock option slash warrant exercises of $10 million and $0.2 million, respectively. We recognize a net loss of 3.6 million for the three months ended September 30th, 2021 or the 2021 quarter compared to a net loss of 3.4 million for the three months ended September 30th, 2020 or the 2020 quarter. The net loss during the 2021 quarter was attributable to operating expenses of 3.8 million, partially offset by the non-cast derivative gain of 0.2 million. The net loss during the 2020 quarter was attributable to operating expenses of $3.3 million and the non-cast derivative loss of $0.1 million. Operating expenses increased $0.5 million for the 2021 quarter as compared to the 2020 quarter, primarily due to a $0.9 million increase in research and development costs, which was driven primarily by an increase in clinical trial expense. partially offset by a 0.4 million decrease in general administrative costs, which was driven primarily by a decrease in legal and commercial insurance costs. We recognize the net loss of 10.8 million for the nine months ended September 30th, 2021, or the 2021 period, compared to a net loss of 3.3 million for the nine months ended September 30, 2020, or the 2020 period. The net loss during the 2021 period was primarily attributable to operating expenses of $11.3 million, partially offset by non-cash derivative gain of $0.5 million. The net loss during the 2020 period was primarily attributable to operating expenses of $11.9 million, Partially offset by the gain realized from the PPP loan forgiveness of 0.5 million and a non-cash derivative gain of 0.1 million. The operating expenses decreased 0.6 million for the 2021 period as compared to the 2020 period due to a decrease in administrative costs. On September 30th, 2021, there were 200.5 million common shares outstanding compared to approximately 193.4 million shares on December 31, 2020. The increase during the nine months ended September 30th, 2021 is attributable to issuance of shares under the ATM Equity Offering Program, which approximated about 6.3 million shares and an average price of $1.67 a share, and also warrant and stock option exercises accounted for about 0.8 million shares. And lastly, based on our current projection, which includes but is not limited to access to the residual capacity under the ATM of approximately $13.3 million, Ampio expects to have cash and cash equivalents sufficient to fund research and development programs and business operations through the first quarter of 2023. And now I'll turn the call over to Holly Turevka, Ampio's President and Chief Operating Officer, who will provide a business update on the company's clinical and research pipeline and other business matters.

Thank you, Dan. Thank you everyone for joining the call today. This has been an active quarter and we are excited to provide corporate updates. First, we have strengthened our executive board and executive management team. It is our pleasure to welcome Michael Martino, Kevin Bucci, and Dr. Howard Levy to the team. Mr. Martino has nearly four decades of pharmaceutical experience. He has led the development of drugs and devices to treat and diagnose inflammatory, autoimmune, and oncology diseases. He has filled roles at multibillion-dollar specialty pharmaceutical companies in finance, marketing, strategic planning, business development, and general management. He has served as CEO of both private and public small drug development companies, where he has led development from preclinical through Phase III clinical trials, transacted mergers, and raised nearly $1 billion in capital through collaborative R&D agreements and financing with institutional investors. Mr. Bucci brings a breadth of public company pharmaceutical experience and a history of driving shareholder value. He notably progressed from chief financial officer to chief operating officer and ultimately chief executive officer at Cefalon. Under his tutelage, Mr. Bucci successfully secured a multibillion-dollar exit for the company's shareholders by executing a transaction that included therapeutic areas in pain management, respiratory, CNS, oncology, and a biologic candidate in inflammatory disease. Dr. Levy brings an added layer of regulatory, medical, and scientific knowledge as an MD-PhD pulmonologist with over a decade as hospital chief of critical care medicine. along with a wealth of U.S. Federal Drug Administration, or FDA, experience, most applicably with significant experience in drug development in the Center for Biologics Evaluation and Research, or CBER, Division of the FDA. Dr. Levy's past experiences as the Chief Medical Officer of Catalyst Biosciences Incorporated, a biopharmaceutical company focused on developing novel therapies targeting the innate immune system to treat unmet medical needs, and as the Senior Global Medical Program Director at CSL Bering, a multibillion-dollar pharmaceutical company focused on plasma-derived and recombinant therapies. provide unique and specific insight into successful medical development under the direction and review of the CBER Division of the FDA. Dr. Levy brings with him to the role of Chief Medical Officer at Ampio Pharmaceuticals expertise in critical illness, particularly in multiple organ failure with emphasis in respiratory viruses and pneumonia and a robust background developing blood products. Adding to the executive management team at this time is critical, as we believe the company is in the latest phase of development for Ampion, a groundbreaking therapy as the first novel mechanism of action for osteoarthritis patients in nearly a quarter of a century. Osteoarthritis patients desperately need a novel approach to the uncurable disease paradigm. To that end, the FDA has provided written agreement that pivotal study AP3A is an adequate and well-controlled clinical trial that provides evidence of effectiveness of Ampion and can contribute to the substantial evidence of effectiveness necessary for approval of a biologics license application known as a BLA. The company has received a special protocol assessment, known as a SPA, agreement from the FDA on the AP13 study with concurrence on the trial design as a confirmatory study of Ampion in osteoarthritic patients. This study was initiated in June of 2019 prior to the onset of the COVID-19 pandemic. During the conduct of the AP13 study, the FDA recognized the January 2020 Health and Human Service declaration of a public state of emergency due to COVID-19 and its impact on clinical trials, which the agency addressed in Guidance for Industry. In addition to the Guidance for Industry, the FDA has provided the company with guidance on the AP13 clinical program in light of the COVID-19 health emergency. The company has closed the AP13 clinical database and is currently analyzing the data from the study based on both public guidance and specific guidance from the FDA on the Ampion Osteoarthritis Program with the goal to have a meeting with the FDA in the first half of 2022. In addition to providing evidence of safety and efficacy in pain and function, preclinical and early clinical studies have shown that Ampion impacts multiple genes related to repair and regeneration of cartilage. These published findings suggest that Ampion treatment may prime stem cells for both mobilization and chondrogenic differentiation, potentially explaining some of the beneficial effects achieved in clinical trials with Ampion treatment. For example, data published in a peer-reviewed journal titled Patient Safety in Surgery showed a significant reduction in pain and a lower rate of total knee replacement with Ampion treatment compared to saline control in osteoarthritis of the knee patients and a Phase I-II study with long-term follow-up for more than three years. MRI analysis of these patients demonstrated potential cartilage preservation with Ampion treatment compared to saline, representing potential for disease modification. Patients treated with Ampion had less cartilage loss than patients treated with saline in all pre-specified anatomically defined regions of the knee. Ampion also showed increased cartilage thickness in two lateral subregions. Ampion's positive impact on pain and functionality, including in patients with severe disease, may be driven in part by these regenerative effects of Ampion on cartilage deposition and restoration in the joints. In addition to this osteoarthritis program, the ability to successfully demonstrate strong in vitro data has supported an expedited regulatory path into human clinical trials for respiratory distress due to COVID-19. This was presented in a scientific forum at the International Society for Aerosols and Medicines, also known as ISAM, in a report titled Regulatory Decisions During COVID-19, Efficient Non-Clinical Inhalation Toxicology for a Clinical Program, which supports the Ampion inhalation program for the treatment of respiratory distress due to COVID-19. Currently, Ampion is being investigated as a potential inhalation treatment for patients with severe COVID in a hospital setting in the AP-19 clinical study under a U.S. FDA IND. This study protocol was reviewed by the FDA for consideration in support of a potential emergency use authorization, or EUA, for the treatment of COVID-19 patients. The first patient in the AP-19 study was enrolled and treated in the United States, and following the regulatory approval from the Drugs Controller General of India, enrollment and patient treatment has commenced in India starting in October of this year. The clinical trial is currently designed to enroll 200 patients with an interim analysis after 150 patients have been enrolled and completed the 28-day visit to allow for evaluation and sample size re-estimation as appropriate. It is anticipated that enrollment for the interim analysis will be completed in the second quarter of 2022. Also evaluated by the FDA for consideration as a potential EUA treatment in the fight against COVID-19 is the Phase II AP17 clinical study for the intravenous treatment of Ampion in hospitalized COVID-19 patients. This study is currently designed to enroll 200 patients with an interim analysis designed to evaluate 40 patients and include sample size re-estimation as applicable. The interim analysis population will be enrolled by early first quarter. Additionally, the inhaled treatment of Ampron is being investigated in a randomized controlled phase one study for at-home use among COVID patients. This study aims to evaluate Ampion treatment compared to control in 30 long COVID patients. The company believes enrollment for this study will be completed by the end of the year. The clinical trials and the investigation of Ampion as a possible treatment for respiratory distress in COVID-19 patients is supported by Ampion data and supplementary publications in peer-reviewed scientific journals. Most recently, the data from a randomized controlled phase one trial, which was conducted to evaluate hospitalized patients with respiratory distress due to COVID-19, was published in the peer-reviewed journal titled Infectious Diseases and Therapy. Patients in this study received the standard of care for COVID-19, including respiratory therapy, corticosteroids, and antiviral therapies. Patients were randomized one-to-one to inhalation treatment with Ampion as an adjunct to standard of care or to standard of care alone as control. Ampion was administered via inhalation daily for five days. Safety and clinical efficacy endpoints were evaluated. Forty subjects were enrolled and randomized in the study, and it was observed that antiviral therapy was required in fewer Ampion-treated subjects, 26%, compared to 52% in control, and steroids were administered for most subjects. The study met its primary endpoint with no Ampion treatment-related adverse events, and the incidence and severity of adverse events were comparable between groups. Notably, compared to control, subjects treated with Ampion had fewer deaths, 5% compared to 24% in the control arm. Shorter hospital stay, 8 days versus 12 days, fewer ICU admissions, 21% versus 33%, and a greater proportion of patients treated with Ampion had improved clinical outcomes compared to control. The Phase I clinical results indicate inhaled Ampion is safe, well-tolerated, and could lead to fewer patients experiencing deterioration or death due to COVID-19. In addition to the ongoing clinical investigations for Ampion treatment in inflammatory disease, the company has continued to strengthen the Ampion platform technology research and development pipeline, most recently presenting preclinical data and potential application for Ampion in acute kidney injury, known as AKI, and lupus nephritis in scientific forums. This clinical and preclinical activity is supported by robust in-house manufacturing. The manufacturing team recently delivered a presentation titled Pivoting from One to Multiple Production Platforms to Treat COVID-19 at the 2021 International Society for Pharmaceutical Engineers, known as the ISPE, at the annual meeting and expo in Boston, Massachusetts, this November. The presentation reports Ampio's innovative work, which has significantly and rapidly expanded the capabilities of its wholly owned, automated drug manufacturing facility that was initially focused on producing 4cc vials of the platform immunomodulatory drug Ampion for interarticular injections into patients with osteoarthritis of the knee. In less than four months, the manufacturing facility was reprogrammed to manufacture Ampion products to support clinical development in osteoarthritis, along with development in COVID-19 and preclinical application. With these updates and the continued progress and forward momentum from the company, it is my pleasure to introduce you to Dr. Levy for an update from our Chief Medical Officer.